Partnerships · healthcare · LATAMJul 20269 min read327 words

The 12 most common partnerships and co-selling mistakes and how to fix them for healthcare and life sciences in Latin America

Every mistake we see teams make with partnerships and co-selling — starting with the ones that cost the most and are the cheapest to fix. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

Every partnerships and co-selling failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.

Mistake one, the foundational one: signing MOUs no one operationalises. Fix by naming an owner and writing kill criteria before you spend a dollar.

Mistake two: mistaking volume for progress. Fix by making sourced and influenced pipeline from partners the only weekly headline number.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.

Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.

Mistake five: ignoring the trigger. Partnerships and co-selling works when one great partner is worth ten marketing hires; without a real trigger the model is guesswork.

Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.

Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.

B2B partnershipsco-sellingchannelB2B partnerships mistakesB2B partnerships pitfallsB2B partnerships for healthcare and life sciencesB2B partnerships in Latin Americahealthcare and life sciences growth in Latin America

Frequently asked questions

Partnerships · healthcare · LATAM — answered

Does partnerships and co-selling work for healthcare and life sciences in Latin America?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
What is the most expensive partnerships and co-selling mistake?
Signing MOUs no one operationalises — because it silently degrades every downstream metric.
Which mistake is cheapest to fix?
Missing kill criteria. Write them in an hour and save a quarter of budget.
Can I skip the quality gate?
Not in the first four weeks. After the model is proven, you can automate parts of it.
How do I know a mistake is compounding?
Sourced and influenced pipeline from partners stalls or drops for two consecutive weeks. That is your alarm.
What is the LATAM-specific pitfall when running partnerships and co-selling for healthcare?
Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.

Growth Broker editorial

Filed under partnerships · healthcare · latam

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call